Pediatric Nutrition — Practice MCQs Free For You All

Section 1: Questions

Q1. According to WHO/AAP recommendations, exclusive breastfeeding should be continued for the first:

A. 3 months

B. 4 months

C. 6 months

D. 12 months

Q2. Deficiency of which vitamin is the classic cause of nutritional rickets in infants?

A. Vitamin A

B. Vitamin C

C. Vitamin D

D. Vitamin K

Q3. What is the recommended daily vitamin D supplementation dose for exclusively and partially breastfed infants?

A. 100 IU/day

B. 200 IU/day

C. 400 IU/day

D. 1000 IU/day

Q4. Vitamin K is administered at birth primarily to prevent which condition?

A. Neonatal jaundice

B. Vitamin K deficiency bleeding (hemorrhagic disease of the newborn)

C. Necrotizing enterocolitis

D. Neonatal sepsis

Q5. A child presents with generalized edema, hypoalbuminemia, a fatty liver, and skin/hair changes, but has been receiving adequate calories with very low protein intake. This is most consistent with:

A. Marasmus

B. Kwashiorkor

C. Vitamin A deficiency

D. Scurvy

Q6. Marasmus differs from kwashiorkor in that marasmus is characterized by:

A. Prominent edema with preserved muscle mass

B. Severe wasting of fat and muscle without edema, due to deficiency of both calories and protein

C. Normal weight-for-height with fatty liver

D. Isolated micronutrient deficiency only

Q7. In a well infant, which laboratory marker is the most sensitive early indicator of depleted iron stores before anemia develops?

A. Serum ferritin

B. Hemoglobin

C. Mean corpuscular volume (MCV)

D. Reticulocyte count

Q8. Exclusively breastfed term infants are generally recommended to start iron supplementation or iron-rich complementary foods by what age?

A. 1 month

B. 4 months

C. 9 months

D. 12 months

Q9. A malnourished child presents with dry conjunctivae, Bitot spots, and corneal xerosis progressing toward keratomalacia. This is due to deficiency of:

A. Vitamin A

B. Vitamin B1 (thiamine)

C. Vitamin D

D. Vitamin E

Q10. A child with poor dietary vitamin C intake presents with gum swelling/bleeding, perifollicular hemorrhages, and corkscrew body hairs. The diagnosis is:

A. Scurvy

B. Rickets

C. Pellagra

D. Beriberi

Q11. Perioral and acral erythematous, scaly/vesiculobullous dermatitis with diarrhea and alopecia in an infant is classically associated with deficiency of:

A. Zinc

B. Copper

C. Selenium

D. Iodine

Q12. An infant on prolonged fat-restricted parenteral nutrition without adequate lipid develops a dry, scaly rash, poor growth, and thrombocytopenia. This is most consistent with deficiency of:

A. Essential fatty acids (linoleic acid)

B. Vitamin E

C. Biotin

D. Vitamin B12

Q13. During nutritional rehabilitation of a severely malnourished child, the electrolyte abnormality most characteristic of refeeding syndrome is:

A. Hyperphosphatemia

B. Hypophosphatemia

C. Hypernatremia

D. Hypercalcemia

Q14. In chronic protein-energy malnutrition, which anthropometric parameter is affected LAST (most preserved)?

A. Weight

B. Height/length

C. Head circumference

D. Mid-upper arm circumference

Q15. Failure to thrive is most commonly identified on growth charts by:

A. A single weight measurement at the 25th percentile

B. Weight persistently below the 3rd–5th percentile or crossing down two major percentile lines over time

C. Head circumference above the 95th percentile

D. Height above the 90th percentile

Q16. Periconceptional supplementation with which micronutrient reduces the risk of neural tube defects?

A. Folate (folic acid)

B. Vitamin B12

C. Iodine

D. Vitamin D

Q17. An exclusively breastfed infant of a strict vegan mother (with no B12 supplementation) presents with pallor, developmental regression, and macrocytic anemia. The most likely deficiency is:

A. Vitamin B12 (cobalamin)

B. Folate

C. Iron

D. Vitamin B6

Q18. WHO growth standards use weight-for-age, length/height-for-age, weight-for-length/height, and BMI-for-age primarily to assess a child’s:

A. Immunization status

B. Nutritional status and growth pattern

C. Developmental milestones

D. Bone age

Q19. The first-line dietary management for an infant with confirmed cow’s milk protein allergy who is not exclusively breastfed is:

A. Soy-based formula

B. Extensively hydrolyzed formula (or amino acid–based formula if severe/refractory)

C. Whole cow’s milk diluted with water

D. Goat’s milk formula

Q20. Childhood obesity is defined as a BMI-for-age and sex at or above which percentile on standard growth charts?

A. 50th percentile

B. 75th percentile

C. 85th percentile

D. 95th percentile

Section 2: Answer Key, Explanations & High-Yield Pearls

Q1. According to WHO/AAP recommendations, exclusive breastfeeding should be continued for the first:

Correct Answer: C. 6 months

Explanation: Exclusive breastfeeding (no other liquids or solids, only breast milk) is recommended for the first 6 months of life, with continuation of breastfeeding alongside complementary foods up to 1 year of age or beyond.

High-Yield Pearl: Complementary feeding should begin around 6 months — introduced too early, it displaces breast milk and increases infection risk; too late, it risks micronutrient deficiency (especially iron and zinc).

Q2. Deficiency of which vitamin is the classic cause of nutritional rickets in infants?

Correct Answer: C. Vitamin D

Explanation: Vitamin D deficiency impairs intestinal calcium and phosphate absorption, leading to defective mineralization of growing bone (rickets) and, in adults, osteomalacia.

High-Yield Pearl: Exclusively breastfed infants, dark-skinned infants, and those with minimal sun exposure are at highest risk — hence universal vitamin D supplementation from birth.

Q3. What is the recommended daily vitamin D supplementation dose for exclusively and partially breastfed infants?

Correct Answer: C. 400 IU/day

Explanation: All breastfed and partially breastfed infants should receive 400 IU/day of oral vitamin D beginning in the first few days of life, continued until the infant is weaned to at least 1 L/day (about 1 quart) of vitamin D–fortified formula or whole milk.

High-Yield Pearl: Formula-fed infants taking less than 1 L/day of fortified formula also need supplementation — fortified formula alone rarely meets the requirement until intake is substantial.

Q4. Vitamin K is administered at birth primarily to prevent which condition?

Correct Answer: B. Vitamin K deficiency bleeding (hemorrhagic disease of the newborn)

Explanation: Newborns have low vitamin K stores, poor placental transfer, and sterile gut flora (which normally synthesizes vitamin K), predisposing them to bleeding. A single intramuscular dose of vitamin K at birth prevents early, classic, and late forms of vitamin K deficiency bleeding.

High-Yield Pearl: Late VKDB (2–12 weeks) can present with intracranial hemorrhage and is strongly associated with exclusive breastfeeding without vitamin K prophylaxis — oral regimens are less reliable than a single IM dose.

Q5. A child presents with generalized edema, hypoalbuminemia, a fatty liver, and skin/hair changes, but has been receiving adequate calories with very low protein intake. This is most consistent with:

Correct Answer: B. Kwashiorkor

Explanation: Kwashiorkor results from severe protein deficiency in the presence of relatively adequate energy (calorie) intake. It produces edema (from hypoalbuminemia), hepatomegaly with fatty infiltration, skin depigmentation/desquamation, and sparse, discolored (‘flag sign’) hair.

High-Yield Pearl: The edema of kwashiorkor can mask underlying wasting and make the child appear less malnourished than they are — always check for pitting edema and serum albumin when assessing severe malnutrition.

Q6. Marasmus differs from kwashiorkor in that marasmus is characterized by:

Correct Answer: B. Severe wasting of fat and muscle without edema, due to deficiency of both calories and protein

Explanation: Marasmus is a global energy/protein deficiency leading to severe loss of subcutaneous fat and muscle wasting (‘skin and bones’ appearance) without the edema seen in kwashiorkor.

High-Yield Pearl: Marasmic kwashiorkor (mixed form, with both wasting and edema) carries the highest mortality risk among severe acute malnutrition presentations.

Q7. In a well infant, which laboratory marker is the most sensitive early indicator of depleted iron stores before anemia develops?

Correct Answer: A. Serum ferritin

Explanation: Serum ferritin reflects total body iron stores and falls before hemoglobin or MCV change, making it the earliest marker of iron depletion (though it can be falsely elevated as an acute-phase reactant during inflammation).

High-Yield Pearl: Iron deficiency progresses in stages: depleted stores (↓ferritin) → iron-deficient erythropoiesis (↓transferrin saturation) → iron deficiency anemia (↓Hgb, microcytosis) — hemoglobin alone misses the earliest stage.

Q8. Exclusively breastfed term infants are generally recommended to start iron supplementation or iron-rich complementary foods by what age?

Correct Answer: B. 4 months

Explanation: Breast milk iron content, while well absorbed, is low, and fetal iron stores typically last about 4–6 months. The AAP recommends iron supplementation (1 mg/kg/day) for exclusively breastfed infants starting at 4 months until iron-rich complementary foods (such as iron-fortified cereal or pureed meats) are reliably introduced.

High-Yield Pearl: Preterm infants have lower iron stores at birth and need earlier, higher-dose iron supplementation (typically starting by 2 weeks to 1 month of age).

Q9. A malnourished child presents with dry conjunctivae, Bitot spots, and corneal xerosis progressing toward keratomalacia. This is due to deficiency of:

Correct Answer: A. Vitamin A

Explanation: Vitamin A deficiency causes xerophthalmia — a spectrum from night blindness and conjunctival xerosis to Bitot spots (foamy, keratinized conjunctival patches) and, if untreated, corneal ulceration/keratomalacia leading to irreversible blindness.

High-Yield Pearl: Vitamin A deficiency also impairs immune function and increases mortality from measles and diarrheal disease — WHO recommends vitamin A supplementation with measles treatment in deficient populations.

Q10. A child with poor dietary vitamin C intake presents with gum swelling/bleeding, perifollicular hemorrhages, and corkscrew body hairs. The diagnosis is:

Correct Answer: A. Scurvy

Explanation: Vitamin C is a cofactor for collagen hydroxylation; its deficiency (scurvy) impairs collagen synthesis, producing gingival bleeding, perifollicular hemorrhages, corkscrew hairs, and subperiosteal hemorrhage causing bone pain and pseudoparalysis in infants.

High-Yield Pearl: Infantile scurvy classically presents with irritability and pseudoparalysis of the legs from painful subperiosteal hemorrhage, often mistaken for non-accidental trauma.

Q11. Perioral and acral erythematous, scaly/vesiculobullous dermatitis with diarrhea and alopecia in an infant is classically associated with deficiency of:

Correct Answer: A. Zinc

Explanation: Zinc deficiency (acquired or the inherited form, acrodermatitis enteropathica) causes a characteristic triad of periorificial/acral dermatitis, diarrhea, and alopecia, along with growth failure and impaired immune function.

High-Yield Pearl: Zinc deficiency should be considered in infants with unexplained perioral dermatitis plus poor growth — treatment with oral zinc produces dramatic skin improvement within days.

Q12. An infant on prolonged fat-restricted parenteral nutrition without adequate lipid develops a dry, scaly rash, poor growth, and thrombocytopenia. This is most consistent with deficiency of:

Correct Answer: A. Essential fatty acids (linoleic acid)

Explanation: Essential fatty acid (linoleic/linolenic acid) deficiency occurs with prolonged fat-free parenteral nutrition or severe fat malabsorption, producing dry scaly dermatitis, alopecia, poor wound healing, growth failure, and thrombocytopenia.

High-Yield Pearl: Essential fatty acid deficiency can develop within 1–2 weeks in infants on fat-free parenteral nutrition because of their high metabolic demand and limited fat stores — hence lipid emulsions are started early in neonatal PN.

Q13. During nutritional rehabilitation of a severely malnourished child, the electrolyte abnormality most characteristic of refeeding syndrome is:

Correct Answer: B. Hypophosphatemia

Explanation: Refeeding after prolonged starvation triggers an insulin surge that drives phosphate (along with potassium and magnesium) intracellularly, causing severe hypophosphatemia, which can lead to cardiac dysfunction, respiratory failure, and hemolysis.

High-Yield Pearl: In severe acute malnutrition, nutritional rehabilitation must be introduced cautiously and gradually with close monitoring/replacement of phosphate, potassium, and magnesium — aggressive early refeeding is a preventable cause of death.

Q14. In chronic protein-energy malnutrition, which anthropometric parameter is affected LAST (most preserved)?

Correct Answer: C. Head circumference

Explanation: In progressive chronic malnutrition, weight is affected first (wasting), followed by linear growth/height (stunting) if malnutrition persists, with head circumference relatively spared until malnutrition is severe and prolonged, since brain growth is preferentially protected.

High-Yield Pearl: Weight-for-height identifies acute wasting, while height-for-age identifies chronic stunting — using both classifies malnutrition as acute, chronic, or acute-on-chronic.

Q15. Failure to thrive is most commonly identified on growth charts by:

Correct Answer: B. Weight persistently below the 3rd–5th percentile or crossing down two major percentile lines over time

Explanation: Failure to thrive (poor weight gain/growth faltering) is defined using serial measurements — either weight sustained below the 3rd–5th percentile for age, or a downward crossing of two or more major percentile lines on the growth chart, rather than a single low value.

High-Yield Pearl: A single low percentile can simply reflect a small, constitutionally normal child — the trend over serial visits is what distinguishes true growth faltering from normal variation.

Q16. Periconceptional supplementation with which micronutrient reduces the risk of neural tube defects?

Correct Answer: A. Folate (folic acid)

Explanation: Folate is essential for DNA synthesis and neural tube closure, which occurs very early in pregnancy. Periconceptional folic acid supplementation (started before conception and continued through early pregnancy) significantly reduces the risk of neural tube defects such as spina bifida and anencephaly.

High-Yield Pearl: Women with a prior pregnancy affected by a neural tube defect are advised a much higher folic acid dose (4 mg/day) starting at least one month before conception, compared with the standard 0.4 mg/day for average-risk pregnancies.

Q17. An exclusively breastfed infant of a strict vegan mother (with no B12 supplementation) presents with pallor, developmental regression, and macrocytic anemia. The most likely deficiency is:

Correct Answer: A. Vitamin B12 (cobalamin)

Explanation: Maternal vitamin B12 stores are the sole source for an exclusively breastfed infant; strict maternal vegan diets without B12 supplementation lead to low breast milk B12, producing infantile megaloblastic anemia along with irritability, hypotonia, and developmental regression/failure to thrive.

High-Yield Pearl: Neurologic manifestations of infantile B12 deficiency can be more prominent and may precede or occur without significant anemia — a high index of suspicion is needed in breastfed infants of vegan mothers.

Q18. WHO growth standards use weight-for-age, length/height-for-age, weight-for-length/height, and BMI-for-age primarily to assess a child’s:

Correct Answer: B. Nutritional status and growth pattern

Explanation: These four anthropometric indices, plotted on standardized growth curves, are used together to evaluate whether a child’s growth and nutritional status are appropriate, and to detect wasting, stunting, underweight, or overweight/obesity.

High-Yield Pearl: The WHO standards (based on breastfed infants from multiple countries) are preferred for children under 2 years as a ‘growth standard,’ while CDC/WHO hybrid or national references are commonly used for older children.

Q19. The first-line dietary management for an infant with confirmed cow’s milk protein allergy who is not exclusively breastfed is:

Correct Answer: B. Extensively hydrolyzed formula (or amino acid–based formula if severe/refractory)

Explanation: Extensively hydrolyzed protein formulas are first-line for most infants with cow’s milk protein allergy; amino acid–based (elemental) formulas are reserved for infants with severe presentations (e.g., anaphylaxis, eosinophilic esophagitis, or failure to improve on hydrolyzed formula).

High-Yield Pearl: Soy formula is not recommended as first-line therapy for cow’s milk protein allergy because a significant proportion of affected infants (especially with non-IgE-mediated disease) also react to soy protein.

Q20. Childhood obesity is defined as a BMI-for-age and sex at or above which percentile on standard growth charts?

Correct Answer: D. 95th percentile

Explanation: In children and adolescents, obesity is defined as BMI ≥ 95th percentile for age and sex; a BMI between the 85th and <95th percentile is classified as overweight.

High-Yield Pearl: Unlike in adults, fixed BMI cutoffs cannot be used in children because body composition changes with age — percentile-based, age- and sex-specific charts are required for correct classification.

The Blood That Baffled Science for 50 Years is Solved Now

Hey there, I have an amazing tooltip !

MAL Blood Group  ·  Published in Blood Journal  ·  2024

In 1972, a routine blood test on a pregnant woman yielded something deeply puzzling: her red blood cells were missing a surface molecule that existed on every other known human blood sample of the time. Doctors noted the anomaly, filed it away, and moved on. They had no framework to explain it.

For the next five decades, that molecular absence lingered as an open question in the world of hematology — a quiet mystery buried in the archives of transfusion medicine. Then, in 2024, a team of researchers from the United Kingdom and Israel finally cracked it, identifying an entirely new human blood group system and solving one of the field’s longest-standing puzzles.

More Than Just A and B

Most of us learned about blood types in school: A, B, AB, and O, with a positive or negative Rh factor tacked on. But that picture is far from complete. Human blood cells are coated in a complex landscape of proteins and sugars called antigens — and scientists use these antigen patterns to classify blood into different “group systems.” The ABO and Rh systems are simply the most medically well-known of a much larger family.

To date, researchers have identified 47 such blood group systems in humans. Most of the major ones were catalogued in the early 20th century, but new systems continue to emerge — typically rare, typically tied to a small number of individuals worldwide, and typically uncovered when something goes unexpectedly wrong during a blood transfusion.

Quick Facts — Human Blood Group Systems

  • Humans have 47 recognised blood group systems, not just ABO and Rh.
  • Blood group systems are defined by distinct antigen molecules on the surface of red blood cells.
  • Over 99.9% of people carry the AnWj antigen — meaning those without it are extraordinarily rare.
  • The newly identified system is called MAL, after the myelin and lymphocyte protein that hosts the AnWj antigen.
  • Patients who are AnWj-negative risk severe immune reactions if given AnWj-positive blood during a transfusion.

The AnWj Antigen — A Puzzle Without a Gene

The molecule missing from that 1972 patient’s blood was eventually given a name: the AnWj antigen. Scientists confirmed that more than 99.9 percent of people carry it — making those without it extraordinarily rare. But despite decades of awareness, no one could identify the gene responsible for producing it. Without a genetic explanation, it was impossible to develop a reliable test to screen for AnWj-negative patients before transfusions — leaving those individuals vulnerable to potentially severe immune reactions if given incompatible blood.

That gap was both a scientific frustration and a genuine clinical risk. Transfusion reactions can range from mild discomfort to life-threatening organ damage. For patients whose blood type falls outside known systems, matching compatible donors is extraordinarily difficult — often relying on informal networks and a great deal of luck.

It represents a huge achievement, and the culmination of a long team effort, to finally establish this new blood group system and be able to offer the best care to rare, but important, patients.— Louise Tilley, Hematologist, NHS Blood and Transplant

The Breakthrough: The MAL Gene

The team — led by senior research scientist Louise Tilley of NHS Blood and Transplant, with colleagues from the University of Bristol and collaborators in Israel — spent nearly two decades piecing together the puzzle. Their breakthrough came when they traced the AnWj antigen to a specific protein: the myelin and lymphocyte protein, encoded by the MAL gene.

When both copies of a person’s MAL gene carry mutated versions, the AnWj antigen is absent from their blood entirely. This is the inherited form of AnWj-negativity — and it is what that 1972 patient almost certainly had. Importantly, the researchers also found that in some cases, the MAL gene can be functionally suppressed by other underlying conditions, such as certain blood cancers or autoimmune disorders. This means that a newly AnWj-negative result in a patient could sometimes be a flag pointing toward a deeper, undiagnosed illness.

The study, published in Blood, the journal of the American Society of Hematology, confirmed that all AnWj-negative patients studied shared the same mutation pattern — and crucially, that no other cell abnormalities or diseases were linked to the inherited form of the condition.

A 50-Year Timeline

Why This Matters Beyond the Lab

For the handful of individuals worldwide who are AnWj-negative, this discovery is potentially life-changing. Previously, their rare blood type made surgical procedures, childbirth, or any situation requiring a transfusion a logistical and medical challenge. Identifying compatible donors without a genetic test was a matter of laborious manual screening — if it was possible at all.

Now, with the MAL gene identified, blood banks and hospitals can develop targeted genetic tests to identify AnWj-negative patients proactively — before a transfusion crisis occurs. It also allows clinicians to distinguish between patients who are AnWj-negative due to an inherited mutation (a stable, lifelong condition) and those whose MAL expression has been suppressed by illness, which may require a very different medical response.

Tilley acknowledged the difficulty of the research: “The work was difficult because the genetic cases are very rare.” Rare cases, by definition, generate little data, making statistical patterns harder to detect and genetic links harder to confirm. That the team persisted across two decades speaks to both the scientific importance of the question and the very real human stakes attached to it.

The Bigger Picture: Blood Is Still Surprising Us

The MAL discovery arrives on the heels of another recent milestone. In 2022, researchers described the Er blood group system — yet another rare system affecting a small number of people globally. Together, these findings are a reminder that human biology, even in something as fundamental as blood, continues to yield surprises. Each new blood group system identified is not merely a scientific footnote; it represents a population of patients who were previously invisible to modern medicine’s tools.

Understanding these rare variants matters because it builds the infrastructure for safer, more personalised transfusion medicine. It means fewer unexplained reactions, fewer desperate searches for compatible donors, and more patients receiving care that is genuinely matched to their biology.

Half a century after a pregnant woman’s unusual blood sample puzzled a doctor somewhere in the world, science finally has an answer.

The MAL blood group system is now the 47th addition to our understanding of human blood — a testament to the slow, painstaking, but ultimately rewarding work of science. And for the extraordinarily rare individuals who carry this invisible distinction in their veins, it may mean the difference between a routine transfusion and a medical emergency.

Based on research published in Blood, American Society of Hematology, 2024. Research led by Louise Tilley, NHS Blood and Transplant & University of Bristol.

Sometimes, the most important discoveries begin with a single anomaly that refuses to be forgotten.

5 Very Important Abdominal (GI) anomalies in Down syndrome

🚻 Genitourinary (GU) anomalies in Down syndrome

Renal / urinary tract anomalies:

  • Hydronephrosis
  • Vesicoureteral reflux (VUR)
  • Posterior urethral valves (PUV) (in males)
  • Structural renal anomalies (less frequent than cardiac/GI)

External genital anomalies:

  • Cryptorchidism (undescended testes)
  • Hypospadias
  • Smaller genitalia (common phenotypic feature, not a malformation)

🧠 Clinical Pearls (Exam gold)

  • If a neonate with Down syndrome has bilious vomiting → think duodenal atresia first
  • If there is delayed meconium → rule out Hirschsprung disease
  • Always screen:
    • Echocardiography (most important—AV canal defects common)
    • Abdominal ultrasound if symptoms suggest GU involvement

🔑 High-yield GI associations:

  • Duodenal atresia
    • Classic “double bubble” sign on X-ray
    • Presents with early bilious vomiting
  • Hirschsprung disease
    • Failure to pass meconium, abdominal distension
    • Due to absence of ganglion cells in distal colon
  • Annular pancreas
    • Can cause duodenal obstruction
  • Imperforate anus (less common than in VACTERL but reported)

⚠️ Pattern to remember

  • Down syndrome = GI obstruction + Hirschsprung risk
  • GU anomalies are less consistent but still clinically relevant

Kawasaki Disease: Complications & Prognosis

Table of Contents

Complications:

  • Macrophage Activation Syndrome (MAS):
    • Life-threatening hyperinflammation
    • Labs: hyperferritinemia, coagulopathy, thrombocytopenia
    • May mimic MIS-C → needs aggressive immunosuppression
  • Coronary Artery Abnormalities (CAA):
    • Giant aneurysms → myocardial infarction, angina, sudden death
    • Moderate aneurysms → may use dual antiplatelet therapy (aspirin + clopidogrel)
    • Large/giant aneurysms → anticoagulation (warfarin, LMWH) + aspirin
    • Acute thrombosis → thrombolytic therapy
    • Rarely: aneurysm rupture
  • Long-term sequelae of CAA:
    • Coronary stenosis, inducible ischemia → may require CABG or catheter interventions
    • Regressed aneurysms → myointimal thickening, abnormal vascular function

Prognosis:

  • Majority recover fully; timely treatment reduces CAA risk to <5%
  • Recurrence of acute KD: 1–3%
  • Fatality: <1%
  • CAA outcomes:
    • ~50% regress to normal diameter within 1–2 years
    • Giant aneurysms less likely to regress → higher risk thrombosis/stenosis
    • Revascularization or rarely heart transplant may be needed
    • Adult survival with history of giant aneurysms: ~90% at 30 years
  • Children without CAA have normal long-term outcomes
  • Lifestyle & preventive counseling recommended for all KD patients

How to calculate sodium deficit in dehydration?

Hyponatremic Dehydration (Na <130 mEq/L)

Here you calculate sodium deficit explicitly:Na⁺ deficit (mEq)=(135−Serum Na)×0.6×weight (kg)\textbf{Na⁺ deficit (mEq)} = (135 – \text{Serum Na}) \times 0.6 \times \text{weight (kg)}Na⁺ deficit (mEq)=(135−Serum Na)×0.6×weight (kg)

👉 135 mEq/L is taken as desired Na


Example

10 kg child, Na = 125 mEq/L(135−125)×0.6×10=10×6=60 mEq(135 – 125) \times 0.6 \times 10 = 10 \times 6 = \textbf{60 mEq}(135−125)×0.6×10=10×6=60 mEq


Important

  • Correct slowly over 24–48 hrs
  • Max rise: ≤8–10 mEq/L/day
  • Give via DNS / NS + added Na as needed

Isonatremic Dehydration (Na 130–150)

No sodium deficit calculation needed

Instead calculate:

  • Fluid deficit = % dehydration × weight × 10

Example:

  • 10% dehydration in 10 kg child →
    = 10 × 10 × 10 = 1000 mL deficit

Give:

  • Deficit + maintenance + ongoing loss
  • Usually NS / RL initially

Hypernatremic Dehydration (Na >150)

👉 Do NOT calculate sodium deficit
Instead calculate free water deficit:Water deficit (L)=0.6×wt×(Na145−1)\textbf{Water deficit (L)} = 0.6 \times \text{wt} \times \left(\frac{\text{Na}}{145} – 1\right)Water deficit (L)=0.6×wt×(145Na​−1)


Example

10 kg child, Na = 1600.6×10×(160/145−1)≈6×0.103=0.62 L0.6 \times 10 \times (160/145 – 1) \approx 6 \times 0.103 = \textbf{0.62 L}0.6×10×(160/145−1)≈6×0.103=0.62 L


Key Pediatric Pearls (Exam Gold)

  • Hyponatremia → calculate Na deficit
  • Hypernatremia → calculate water deficit
  • Isonatremia → calculate fluid deficit only

Correction Rules

  • Hyponatremia: ↑ Na ≤8 mEq/day
  • Hypernatremia: ↓ Na ≤10–12 mEq/day
  • Rapid correction → ODS (hypo) / cerebral edema (hyper)

How to approach a child with Obesity in Pediatric OPD?

First principle:
👉 Most overweight infants are exogenous (overfeeding).
👉 Investigations are needed only if there are red flags for endocrine, genetic, or metabolic causes.


1️⃣ Step 1: Confirm Overweight / Obesity

Anthropometry

  • Weight-for-length (WHO growth charts)
  • BMI (if >2 years; not for infants)
  • Head circumference
  • Mid-upper arm circumference (optional)

Definitions (WHO)

  • > +2 SD weight-for-length → Overweight
  • > +3 SD → Obese

2️⃣ When to Investigate?

Send investigations if:

  • Rapid weight gain
  • Short length/height (↓ linear growth)
  • Dysmorphic features
  • Developmental delay
  • Hypotonia
  • Organomegaly
  • Hyperphagia
  • Family history of endocrine/genetic disorders
  • Signs of hypothyroidism, Cushing, etc.

If thriving, normal length, normal development → usually no labs required.


3️⃣ Baseline Investigations (If Indicated)

InvestigationWhy Send It
CBCBaseline health
Fasting blood glucoseInsulin resistance (rare in infancy but possible in severe obesity)
Serum insulin (if strong suspicion)Hyperinsulinemia
Lipid profileIf severe obesity or family history
LFT (ALT, AST)NAFLD screening (rare but possible in severe cases)
Thyroid profile (TSH, Free T4)Rule out hypothyroidism
Serum cortisol (8 AM)If Cushing features
IGF-1If growth failure

4️⃣ Endocrine Causes to Rule Out

A. Hypothyroidism

  • TSH
  • Free T4

Clues:

  • Constipation
  • Large tongue
  • Hypotonia
  • Poor linear growth

B. Cushing Syndrome (Very Rare in Infants)

  • 8 AM cortisol
  • Low-dose dexamethasone suppression test (if needed)

Clues:

  • Moon face
  • Hypertension
  • Growth failure
  • Thin skin

C. Hyperinsulinism

  • Fasting insulin
  • Blood glucose

5️⃣ Genetic / Syndromic Evaluation

If:

  • Hypotonia
  • Developmental delay
  • Dysmorphism
  • Hyperphagia

Consider:

  • Karyotype
  • Microarray
  • Referral to genetics

Examples:

  • Prader-Willi syndrome
  • Beckwith-Wiedemann syndrome

6️⃣ Metabolic Screening (If Suspicion)

If:

  • Hepatomegaly
  • Hypoglycemia
  • Recurrent vomiting
  • Developmental delay

Send:

  • Serum ammonia
  • Lactate
  • Tandem mass spectrometry
  • Urine organic acids

7️⃣ If Severe Obesity (> +3 SD)

Consider screening for:

  • Lipid profile
  • LFT (NAFLD)
  • Blood pressure monitoring
  • HbA1c (if strong suspicion)

8️⃣ What NOT to Routinely Send

❌ Insulin levels in every overweight baby
❌ Extensive metabolic panels without red flags
❌ Hormone panels without growth failure


9️⃣ Practical Clinical Algorithm (Exam-Friendly)

Normal length + normal development + formula overfeeding → NO LABS

Overweight + short length → TSH + Free T4

Overweight + hypotonia + hyperphagia → genetic workup

Overweight + moon face + hypertension → cortisol evaluation


🔟 For Your Clinical Practice in Nepal

In most cases in our setup:

  • It is formula concentration error or early complementary feeding.
  • Counseling on feeding practice is more important than investigations.

Here is Treatment: Perforated Acute Otitis Media (AOM with tympanic membrane perforation)

Perforated Acute Otitis Media (AOM with tympanic membrane perforation) is treated slightly differently from uncomplicated AOM because the perforation allows topical therapy to reach the middle ear.


1. First-line Treatment

A. Topical Antibiotic Ear Drops (Most Important)

Use quinolone ear drops because they are safe in perforated TM.

  • Ofloxacin ear drops
    • Dose: 5 drops in affected ear twice daily
    • Duration: 7–10 days

OR

  • Ciprofloxacin ear drops
    • Dose: 4–5 drops twice daily
    • Duration: 7–10 days

Avoid aminoglycoside drops (e.g., Gentamicin, Neomycin) because they can be ototoxic if TM is perforated.


2. Oral Antibiotics (if indicated)

Give systemic antibiotics if:

  • Moderate/severe infection
  • Fever
  • Young child (<2 years)
  • Bilateral disease
  • Systemic symptoms

First line:

  • Amoxicillin
    • 80–90 mg/kg/day divided BID
    • Duration 7–10 days

If severe infection or recent amoxicillin use:

  • Amoxicillin‑clavulanate
    • 90 mg/kg/day (amoxicillin component)

3. Analgesics

  • Paracetamol 10–15 mg/kg every 6 hours
    OR
  • Ibuprofen 10 mg/kg every 8 hours

4. Local Care

  • Keep ear dry (no water entry).
  • Do not plug ear tightly.
  • Gentle ear toilet/suction if discharge excessive.

5. Follow-up

  • Re-examine after 1–2 weeks.
  • Most perforations heal spontaneously within 2–4 weeks.
  • If persistent perforation >6 weeks → ENT referral.

6. Red Flags (Refer ENT)

  • Persistent otorrhea >2 weeks
  • Suspected mastoiditis
  • Hearing loss
  • Recurrent perforations

Example Pediatric Prescription

  • Ofloxacin ear drops: 5 drops BD × 7 days
  • Amoxicillin: 80–90 mg/kg/day divided BD × 7 days
  • Paracetamol: 10–15 mg/kg every 6 hr PRN pain

Cerebral Palsy: Complete Clinical Guide (Causes, Types, Diagnosis and Management)

  • Nelson Textbook of Pediatrics
  • First Aid for the USMLE Step 1
  • Cloherty and Stark’s Manual of Neonatal Care

Introduction


Cerebral palsy (CP) is the most common cause of permanent motor disability in childhood. It results from injury or abnormal development of the immature brain, leading to abnormalities of movement, posture, and coordination.

Despite the term palsy, cerebral palsy is not a progressive disease—the brain injury is static. However, symptoms may change as the child grows.

The worldwide prevalence is approximately 2–3 per 1000 live births, and the condition is more common in premature infants and low-birth-weight neonates.


Overview of Cerebral Palsy

Definition

Cerebral palsy is defined as:

A group of permanent disorders of movement and posture causing activity limitation, attributed to non-progressive disturbances in the developing fetal or infant brain.

Key Characteristics

FeatureDescription
NatureNon-progressive brain injury
OnsetEarly childhood
Primary problemMotor dysfunction
Associated problemsCognitive, sensory, and behavioral issues

Pathophysiology

According to First Aid for the USMLE Step 1, cerebral palsy results from injury to motor control systems of the developing brain.

Brain Areas Involved

Brain StructureResulting Clinical Type
Motor cortexSpastic CP
Basal gangliaDyskinetic CP
CerebellumAtaxic CP
Multiple regionsMixed CP

Mechanisms of Brain Injury

Major mechanisms include:

  • Hypoxic-ischemic injury
  • White matter injury
  • Intracranial hemorrhage
  • Inflammation
  • Toxic injury (bilirubin toxicity)

Periventricular Leukomalacia (Common Mechanism in Preterm Infants)

Periventricular leukomalacia (PVL) is the most common neuropathologic lesion in premature infants who develop CP.

Pathogenesis

  1. Immature cerebral circulation
  2. Hypoxia or ischemia
  3. White matter injury near ventricles
  4. Damage to descending corticospinal tracts

Clinical Outcome

PVL is strongly associated with spastic diplegia.


Etiology of Cerebral Palsy

Modern research shows most CP originates before birth, rather than during delivery.

Causes by Timing of Brain Injury

TimingCauses
PrenatalBrain malformations, infections, genetic disorders
PerinatalPrematurity, birth asphyxia, intracranial hemorrhage
PostnatalInfection, trauma, stroke

Major Risk Factors

Based on Cloherty and Stark’s Manual of Neonatal Care.

Maternal FactorsNeonatal Factors
Maternal infectionPrematurity
Placental insufficiencyLow birth weight
PreeclampsiaNeonatal seizures
Multiple pregnancyIntraventricular hemorrhage

Classification of Cerebral Palsy

Types Based on Motor Pattern

Table: Major Types of Cerebral Palsy

TypeBrain RegionKey FeaturesFrequency
SpasticMotor cortexStiff muscles, hyperreflexia~70–80%
DyskineticBasal gangliaInvoluntary movements~6–10%
AtaxicCerebellumPoor balance and coordination~5–10%
MixedMultiple areasCombination of symptomsVariable

Spastic Cerebral Palsy

Most common type.

Pathophysiology

Damage to corticospinal tracts leads to:

  • Increased muscle tone
  • Hyperreflexia
  • Clonus

Distribution Patterns

TypeBody Areas Involved
HemiplegiaOne side of body
DiplegiaLegs > arms
QuadriplegiaAll limbs
MonoplegiaSingle limb

Dyskinetic Cerebral Palsy

Associated with basal ganglia injury.

Clinical Features

  • Dystonia
  • Chorea
  • Athetosis
  • Involuntary twisting movements

Important Cause

Severe neonatal jaundice causing
Kernicterus.


Ataxic Cerebral Palsy

Results from cerebellar damage.

Symptoms

SymptomDescription
AtaxiaUnsteady walking
Intention tremorTremor during movement
Poor coordinationDifficulty performing fine motor tasks
Wide-based gaitInstability while walking

Clinical Features of Cerebral Palsy

Symptoms depend on severity and brain area affected.

Early Warning Signs

AgeRed Flag
3 monthsPoor head control
6 monthsStiff or floppy muscles
9 monthsNot sitting
12 monthsEarly hand preference

Associated Conditions

Children with CP often have additional neurological problems.

ConditionFrequency
Epilepsy30–50%
Intellectual disability40–60%
Visual impairment20–40%
Speech disorderscommon
Hearing loss10–15%

Diagnosis

Diagnosis is mainly clinical, supported by imaging.

Diagnostic Evaluation

EvaluationPurpose
Developmental historyIdentify delays
Neurological examTone, reflexes
MRI brainIdentify structural lesion
EEGIf seizures present
Genetic testingIf atypical features

Neuroimaging Findings

Common MRI findings include:

  • Periventricular leukomalacia
  • Cortical malformations
  • Brain atrophy
  • Old infarction

Gross Motor Function Classification System (GMFCS)

This system classifies severity of CP.

LevelFunctional Ability
Level IWalks independently
Level IIWalks with limitations
Level IIIWalks with assistive device
Level IVLimited self mobility
Level VWheelchair dependent

Management of Cerebral Palsy

There is no cure, but multidisciplinary management improves function.


Multidisciplinary Treatment

TherapyRole
PhysiotherapyImprove mobility
Occupational therapyDaily living skills
Speech therapyCommunication
Special educationCognitive development

Pharmacological Treatment

Used mainly for spasticity management.

DrugMechanism
BaclofenGABA agonist
DiazepamMuscle relaxant
TizanidineAlpha-2 agonist
Botulinum toxinLocal spasticity control

Surgical Management

Indicated in severe deformities.

Examples include:

  • Tendon lengthening
  • Hip reconstruction
  • Selective dorsal rhizotomy
  • Spinal surgery for scoliosis

Prevention Strategies

Important preventive measures include:

StrategyBenefit
Antenatal carePrevent infections
Prevention of prematurityReduce PVL
Neonatal intensive carePrevent brain injury
Early jaundice treatmentPrevent kernicterus

Prognosis

Outcome depends on:

  • Severity of brain injury
  • Type of cerebral palsy
  • Associated neurological deficits
  • Access to rehabilitation

Many individuals with CP can live productive lives with appropriate therapy and support.


Clinical Pearls (High-Yield)

  • Spastic diplegia → periventricular leukomalacia
  • Dyskinetic CP → basal ganglia injury
  • Ataxic CP → cerebellar damage
  • Kernicterus → dyskinetic cerebral palsy

Conclusion

Cerebral palsy is a lifelong neurological disorder caused by early brain injury. Although the underlying brain damage is permanent, early diagnosis, multidisciplinary therapy, and supportive care can significantly improve functional outcomes and quality of life.


When is lactulose indicated in Wilson disease?

What is wilson disease?

Add lactulose if any of the following are present:

  • Overt hepatic encephalopathy
    • Altered sensorium
    • Irritability, sleep reversal
    • Asterixis
  • Minimal / impending HE
    • Poor school performance
    • Behavioral change
    • Subtle confusion
  • Advanced decompensated liver disease
    • High ammonia levels (if measured)
    • Severe portal hypertension with prior HE
  • Acute liver failure due to Wilson disease

👉 Dose (pediatrics):

  • 0.5–1 mL/kg/dose orally
  • Titrate to 2–3 soft stools/day

When lactulose is NOT needed

Do not add lactulose if the child has:

  • Wilson disease with hepatitis only
  • No encephalopathy
  • Normal mental status
  • Compensated chronic liver disease

Adding lactulose unnecessarily may cause:

  • Diarrhea
  • Electrolyte imbalance
  • Poor compliance

What should be prioritized instead

For Wilson disease with hepatitis, focus on:

Copper chelation

  • D-penicillamine (with pyridoxine)
  • OR Trientine

Zinc therapy (as maintenance or adjunct)

Supportive liver care

  • Low-copper diet
  • Salt restriction if ascites
  • Diuretics if needed
  • Fat-soluble vitamins if cholestasis

Exam-oriented takeaway (very important)

Lactulose is NOT a routine drug in Wilson disease.
It is used only for hepatic encephalopathy, not for hepatitis itself.

MIS-C / MIS-P : Facts and more

Multisystem Inflammatory Syndrome in Children (Pediatric)

It’s a rare but serious inflammatory response, most commonly seen after a COVID-19 infection.

What it is:

An overactive immune response

Causes widespread inflammation affecting multiple organs

Common features:

Persistent fever

GI symptoms (abdominal pain, vomiting, diarrhea)

Rash, red eyes, swollen lips/hands

Heart involvement (myocarditis, low blood pressure)

Fatigue, headache

Timing:

Usually appears 2–6 weeks after a viral infection (classically COVID-19)

Treatment:

Hospital care
IVIG, steroids, anti-inflammatory meds

Most kids recover well with early treatment

If this is about a specific child or symptoms, I can explain warning signs, how it’s diagnosed, or how it differs from Kawasaki disease.

Gotcha — here’s a DM-level (doctor/medical) clinical note on MIS-C (Multisystem Inflammatory Syndrome in Children), written in a professional charting style.

Diagnosis:

Multisystem Inflammatory Syndrome in Children (MIS-C)

Definition:

MIS-C is a post-infectious hyperinflammatory syndrome occurring in pediatric patients, most commonly following SARS-CoV-2 infection. It is characterized by persistent fever, systemic inflammation, and involvement of two or more organ systems.

Epidemiology:

Typically presents in children and adolescents weeks after acute or asymptomatic COVID-19 infection. Incidence is rare but clinically significant due to potential cardiovascular involvement.

Pathophysiology:

Believed to be an immune-mediated response rather than direct viral injury. Dysregulated immune activation leads to cytokine release, endothelial dysfunction, and multisystem inflammation.

Clinical Presentation:

Persistent fever (>38.0°C, ≥24 hours)
Gastrointestinal symptoms (abdominal pain, vomiting, diarrhea)
Mucocutaneous findings (rash, conjunctival injection, strawberry tongue, swollen extremities)
Cardiovascular involvement (myocarditis, depressed ejection fraction, hypotension, shock)
Neurologic symptoms (headache, altered mental status, irritability)
Respiratory symptoms may be minimal or absent

Laboratory Findings:

Elevated inflammatory markers (CRP, ESR, ferritin, procalcitonin)
Lymphopenia, thrombocytopenia
Elevated D-dimer, fibrinogen
Elevated cardiac markers (troponin, BNP/NT-proBNP)
Evidence of recent SARS-CoV-2 infection (PCR or serology)

Diagnosis:

Clinical diagnosis based on CDC/WHO criteria, requiring fever, laboratory evidence of inflammation, multisystem involvement, and temporal association with SARS-CoV-2 infection, with exclusion of alternative diagnoses.

Management:

Hospital admission; PICU if hemodynamically unstable
Immunomodulatory therapy: IVIG and systemic corticosteroids
Supportive care (fluids, vasopressors if indicated)
Anticoagulation in select cases
Cardiology consultation and echocardiographic monitoring

Exit mobile version